Company: Alnylam Pharmaceuticals
Posted by RareDiseaseRep_ALN · March 22, 2026
Tags: compensation, culture
Two years at Alnylam in rare disease.
Honest take: the science is exceptional, the culture is genuinely mission-driven in a way I haven't seen elsewhere, and patients and families remember you.
The downside is the patient populations are tiny so pressure to find new patients is relentless.
There are only so many TTR-amyloidosis patients in a territory and once you've found them you're in a holding pattern.
Comp is competitive — I'm at $142k base with a 20% target bonus.
But the growth trajectory is limited unless you're moving up.
Good place to be if you care deeply about rare disease.
Not ideal if you need volume-driven momentum.
45 upvotes · 6 comments